Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
Neil P. Shah(Unknown), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), John Nicoll, Bhushan Nagar(McGill University), Ronald Paquette, John Kuriyan(Vanderbilt University), M. Gorre
Cited by 1,625